These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12473251)

  • 1. New tricks for an old drug.
    Frenneaux M
    Eur Heart J; 2002 Dec; 23(24):1898-9. PubMed ID: 12473251
    [No Abstract]   [Full Text] [Related]  

  • 2. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide.
    Willoughby SR; Stewart S; Chirkov YY; Kennedy JA; Holmes AS; Horowitz JD
    Eur Heart J; 2002 Dec; 23(24):1946-54. PubMed ID: 12473257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.
    Chirkov YY; Holmes AS; Willoughby SR; Stewart S; Horowitz JD
    Am J Cardiol; 2002 Sep; 90(5):551-4. PubMed ID: 12208424
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris.
    Liberts EA; Willoughby SR; Kennedy JA; Horowitz JD
    Eur J Pharmacol; 2007 Mar; 560(1):49-55. PubMed ID: 17292880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of perhexiline in ischaemic heart failure.
    Noble MI; Drake-Holland AJ
    Int J Cardiol; 2010 Mar; 139(2):105-6. PubMed ID: 19748138
    [No Abstract]   [Full Text] [Related]  

  • 6. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope.
    Phan TT; Shivu GN; Choudhury A; Abozguia K; Davies C; Naidoo U; Ahmed I; Yousef Z; Horowitz J; Frenneaux M
    Eur J Heart Fail; 2009 Sep; 11(9):881-6. PubMed ID: 19656806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation.
    Horowitz JD; Chirkov YY
    Circulation; 2010 Oct; 122(16):1547-9. PubMed ID: 20921436
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
    Singh S; Beadle R; Cameron D; Rudd A; Bruce M; Jagpal B; Schwarz K; Brindley G; Mckiddie F; Lang C; Dawson D; Frenneaux M
    Future Cardiol; 2014 Nov; 10(6):693-8. PubMed ID: 25495811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
    Davies BJ; Coller JK; James HM; Gillis D; Somogyi AA; Horowitz JD; Morris RG; Sallustio BC
    Br J Clin Pharmacol; 2004 Apr; 57(4):456-63. PubMed ID: 15025744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
    Ono H; Kimura M
    Arzneimittelforschung; 1981; 31(7):1131-4. PubMed ID: 7196762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
    Chong CR; Sallustio B; Horowitz JD
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):399-405. PubMed ID: 27106834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide.
    Klinge JM; Topf HG; Trusen B; Rauh M; Rascher W; Dötsch J
    Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide: an emerging role in cardioprotection?
    Rakhit RD; Marber MS
    Heart; 2001 Oct; 86(4):368-72. PubMed ID: 11559670
    [No Abstract]   [Full Text] [Related]  

  • 14. ["Activating blood circulation and removing stasis" in platelet aggregation and congestive heart failure--a topic of clinical research in combined traditional Chinese-western medicine].
    Ye ZM
    Zhong Xi Yi Jie He Za Zhi; 1984 May; 4(5):314-5. PubMed ID: 6236907
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
    Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
    Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process.
    Berkels R; Klaus W; Boller M; Rösen R
    Thromb Haemost; 1994 Aug; 72(2):309-12. PubMed ID: 7831670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of nitric oxide in progression and regression of atherosclerosis.
    Cooke JP
    West J Med; 1996 May; 164(5):419-24. PubMed ID: 8686299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects.
    Dhakal B; Tomita Y; Drew P; Price T; Maddern G; Smith E; Fenix K
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New cardiovascular-active drugs].
    Bölter C
    Z Arztl Fortbild (Jena); 1984; 78(19):797-800. PubMed ID: 6506791
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
    Ling LH; Chik W; Averbuj P; Pati PK; Sverdlov AL; Ngo DT; Morris RG; Sallustio BC; Horowitz JD
    Ther Drug Monit; 2011 Apr; 33(2):251-6. PubMed ID: 21383654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.